Jagsonpal Pharmaceuticals Q4 FY26: 200% Dividend, INR40 Crore Buyback
Jagsonpal Pharmaceuticals Limited delivered strong financial performance for FY26 with revenue growing 7% to INR287 crores and PAT increasing 19% to INR45 crores. Q4 FY26 showed accelerated growth with revenue up 10% to INR64 crores and PAT up 31% to INR9 crores. The board recommended a 200% dividend including a 75% special dividend, alongside an INR40 crores buyback at INR250 per share. The company maintains a strong cash position of over INR190 crores and targets 1.5x Indian Pharma Market growth at 12-15%.
*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026, alongside the earnings conference call transcript for Q4 FY26 held on April 28, 2026. The company declared an impressive 200% dividend, demonstrating strong commitment to shareholder wealth creation, complemented by a share buyback program.
Strong Financial Performance Across Key Metrics
The pharmaceutical company reported robust growth across all major financial parameters for FY26. The performance highlights showcase the company's operational strength and market positioning.
| Metric | FY26 Growth (YoY) | Q4 FY26 Growth (YoY) |
|---|---|---|
| Revenue | 7% | 10% |
| EBITDA | 5% | 9% |
| PAT | 19% | 31% |
For the full year FY26, revenue grew to INR287 crores, operating EBITDA stood at close to INR61 crores with a margin of approximately 21%, and profits from operations reached INR45 crores. In Q4 FY26, revenue grew to INR64 crores, EBITDA to INR11 crores, and PAT to INR9 crores with a PAT margin expanding to approximately 14%.
Shareholder Returns: Dividend and Buyback
The board has recommended a 200% dividend for the year, which includes a one-time special dividend of 75%. This will result in a total payout of INR4 per share and an overall cash distribution of approximately INR26 crores. Additionally, the company announced an INR40 crores buyback of up to 16 lakh equity shares at INR250 per share, with no promoter participation. Shareholder approval for the buyback was received on April 27, 2026, while the enhanced dividend is subject to shareholder approval at the forthcoming AGM.
Between buyback and dividend, the company shall be returning over INR66 crores to shareholders. The buyback is expected to improve ROE from approximately 16% to 18% and ROCE from approximately 22% to close to 26%. The record date for the buyback is May 04, 2026.
Operational Performance and Market Outperformance
On a MAT basis, the company delivered 12.2% growth as per Pharmarack, outperforming the market by 3.6%. This momentum accelerated in Q4, where growth reached 14.2% against industry growth of 10.5%. The company's top 10 brands constitute approximately 58% to 60% of total sales, with nine out of these top 10 brands ranked within the top five in their respective categories. Growth has been led by strong traction across Gynaecology and Dermatology therapies.
Financial Discipline and Balance Sheet Strength
The company maintains a strong balance sheet with a cash position of over INR190 crores as of March 31, 2026. Working capital remains well-managed with a net working capital cycle at close to 11 days. The company continues to scout for strategic inorganic initiatives while maintaining disciplined capital allocation focused on value creation and efficient cash deployment.
Corporate Information and Market Presence
Jagsonpal Pharmaceuticals operates from its corporate office in Gurugram, Haryana, and maintains its registered office in New Delhi. The company trades on both major Indian stock exchanges - BSE (Scrip Code: 507789) and NSE (Symbol: JAGSNPHARM). The company also runs the "My Sakhi" CSR initiative, demonstrating its commitment to social responsibility alongside business growth. Looking ahead, management has provided guidance to grow at 1.5x of the Indian Pharma Market growth, targeting between 12% to 15% growth.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.07% | +3.40% | +4.36% | +5.70% | -5.92% | +398.30% |
Given management's confidence in recouping the INR66 crore payout within 12 months, which specific therapy segments or geographies are most likely to drive the accelerated revenue growth needed to support a potential INR400 crore acquisition?
With Jagsonpal targeting acquisitions of up to INR400 crores using its own balance sheet, what types of companies or assets — branded generics, specialty pharma, or distribution networks — would best complement its existing Gynaecology, Orthopaedics, and Dermatology focus?
As approximately 92% of Jagsonpal's portfolio sits outside NLEM price controls, how vulnerable is the company's pricing-led growth strategy if the government expands the essential medicines list to include more products in its core therapy areas?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
